Trial Profile

A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nirogacestat (Primary)
Indications Ovarian cancer
Focus Therapeutic Use
Sponsors SpringWorks Therapeutics

Most Recent Events

12 Nov 2024 According to a SpringWorks Therapeutics media release, the company expects to report initial data from this trial in 1H 2025.
25 Jul 2024 This trial has been completed in Poland, as per European Clinical Trials Database record.
08 Jan 2024 According to a SpringWorks Therapeutics media release,company expects to report initial data from the trial in the second half of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com